To study the day-night variation of omentin-1 levels and assess whether leptin and/or short-and long-term energy deprivation alter circulating omentin-1 levels via cytokines. DESIGN AND METHODS: Omentin-1 levels were measured hourly in serum samples from six healthy men to evaluate for day-night variation. To study effects of acute energy deprivation and of leptin administration, eight healthy subjects were studied in the fasting state for 72 h with administration of either placebo or metreleptin (recombinant human leptin) in physiologic replacement doses. We evaluated the effect of leptin in pharmacologic doses on serum omentin-1 and cytokine levels, as well as on omentin-1 levels in ex vivo omental adipose tissue, in 15 healthy volunteers. To study the effect of chronic energy deprivation and weight loss on omentin-1 levels, we followed 18 obese subjects for 12 months who underwent bariatric surgery. RESULTS: There is no day-night variation in omentin-1 levels. Short-term and chronic energy deprivation, as well as ex vivo leptin administration and physiologic replacement doses of leptin, do not alter omentin-1 levels; pharmacologic doses of metreleptin reduce omentin-1 levels, whereas levels of tumor necrosis factor-α receptor II and interleukin-6 tend to increase. CONCLUSIONS: Omentin-1 levels are reduced by pharmacologic doses of metreleptin independent of effects on cytokine levels.
INTRODUCTION
Visceral adiposity is associated with a higher risk of metabolic complications of obesity, such as type 2 diabetes mellitus, dyslipidemia and cardiovascular disease, compared with subcutaneous adiposity. [1] [2] [3] In an attempt to identify humoral mediators of this risk, studies were performed to identify genes specifically expressed in human omental adipose tissue. 4, 5 By sequencing complementary DNA from a human fat library, Yang et al. 5 discovered a gene on chromosome 1q21.3 that was selectively expressed in human omental adipose tissue, coding for a 313-amino-acid glycosylated protein, 4 which was named omentin to reflect its preferential expression in the omental adipose tissue. [5] [6] [7] [8] [9] This adipocytokine was later renamed omentin-1 after the discovery of omentin-2, which shares 83% amino-acid homology with omentin-1 but is much less abundant in the plasma. 10 The exact role of omentin-1 in human physiology remains unclear. Cross-sectional human studies have found lower levels of omentin-1 in obese, as compared with lean, individuals, and an inverse correlation with body mass index (BMI), waist-to-hip ratio 8, [10] [11] [12] [13] [14] [15] and insulin resistance. 12, [16] [17] [18] [19] Physiologic studies have suggested that omentin-1 may have a role in the pathogenesis of complications of obesity. For example, the reduced levels of omentin-1 in obesity may be contributing to the higher risk of hypertension through a reduction in vasodilatory effect of omentin-1 on the vasculature. 20, 21 Studies in rodent models have yielded controversial results on whether the changes in omentin-1 levels are secondary or causative to obesity and increased insulin levels. Although a chronic intraperitoneal infusion of omentin-1 led to a significant increase in food intake, weight and altered the related hypothalamic peptides and neurotransmitters in a rat model, 22 injection of omentin-1 into the arcuate nucleus of the hypothalamus in rats did not alter food intake or expression of orexigenic or anorexigenic neuropeptides. 23 Tan et al. 6 demonstrated that glucose and insulin were able to suppress omentin-1 secretion, both in human omental fat explants and in in vivo human experiments. Interestingly, several studies have found a negative correlation between omentin-1 and leptin levels, 10, 13 which persisted even after adjusting for age, sex and body mass index, 10 suggesting a regulatory relationship between these two adipokines outside of the effects of adiposity. 10 However, no interventional study has investigated whether this relationship may be causal nor is there evidence for whether levels vary with feeding or fasting.
In addition to its proposed metabolic role, data from epidemiologic studies demonstrate a negative correlation between omentin-1 serum levels and levels of proinflammatory cytokines, suggesting that omentin-1 could have a role in the immune system. 12, 16 In particular, investigations have focused on a potential role of omentin-1 in moderating the effects of tumor necrosis factor-α (TNF-α). Omentin-1 was found to reduce TNF-αinduced inflammation in vascular smooth muscle cells 24 and 1 human vascular endothelial cells, 25 possibly via prevention of TNF-α-induced cyclooxygenase-2 expression. 26, 27 The purpose of this study is thus to evaluate whether omentin-1 levels exhibit any day-night variation given many adipokines including leptin demonstrate day-night variability, and also to assess whether chronic or acute energy deprivation affects omentin-1 levels and whether metreleptin (recombinant human leptin) administration, in replacement or pharmacologic doses, directly affect circulating omentin-1 levels. In addition, we performed ex vivo experiments evaluating whether direct treatment of omental adipose tissue with leptin could change omentin-1 expression.
MATERIALS AND METHODS
Institutional approval was obtained from the Institutional Review Board of Beth Israel Deaconess Medical Center, and written informed consent was obtained, for all studies. An investigator-initiated Investigational New Drug approval was obtained by Christos Socrates Mantzoros from the US Food and Drug Administration for the use of metreleptin. Studies 1, 3 and 4 are from the same original study but only six subjects in the isocaloric-fed study and only eight subjects in the fasting state with placebo/physiologic metreleptin study had samples available for evaluation.
Subjects
Study 1: Study in the isocaloric-fed state. To evaluate for potential day-night variation pattern in omentin-1 levels, six healthy lean male volunteers were recruited from the community and admitted to the Clinical Research Center (CRC) for 4 days. 28 The participants had no medical problems and did not take any medications. Meals, sleep and other potential confounders were standardized as described previously. 6, 28 From 0800 hours on day 3 to 0800 hours on day 4, blood samples were collected every 15 min. The samples were pooled hourly to satisfy assay sample volume requirements. The samples were stored at − 80°C until assayed.
Study 2: Study in the weight reduced state after bariatric surgery. To evaluate for any effect of prolonged energy deprivation on omentin-1 levels, 18 patients who underwent bariatric surgery (Roux-en-Y or gastric banding) were recruited. Fasting blood samples were obtained between 0800 h and 1000 h preoperatively (n = 18), and at 3, 6 and 12 months after the surgery (n = 16, 16, 10, respectively).
Study 3: Study in the fasting state with placebo/physiologic metreleptin in physiologic doses. To evaluate for any effect of acute energy deprivation on omentin-1 levels, eight lean male volunteers (including the six from Study 1) were admitted to the CRC for two separate 4-day admissions, separated by at least 7 weeks. 28 During these admissions, the participants were kept fasting but were allowed free access to non-caloric noncaffeinated drinks. In addition, they were given a multivitamin, 500 mg of NaCl and 40 mEq of KCl daily. During the two admissions, participants were administered in a randomized, double-blinded manner either placebo or recombinant human leptin (metreleptin). Clinical quality metreleptin was supplied by Amylin Pharmaceuticals LLC (San Diego, CA, USA; a wholly-owned subsidiary of Bristol-Myers Squibb). The daily dose of metreleptin was 0.04 mg kg − 1 per day on day 1, 0.1 mg kg − 1 per day on days 2 and 3 and one dose of 0.025 mg kg − 1 at 0800 hours on the fourth day, with the total daily dose divided into four equal doses given every 6 h starting at 0800 hours on day 1. Blood samples were collected through an indwelling peripheral intravenous line from 0800 hours on day 3 to 0800 hours on day 4, and processed and stored as described for study 1. Omentin-1 levels were assayed in six samples per 24-h period per participant per admission.
Study 4: Study in the fasting state with pharmacologic doses of metreleptin.
To evaluate for any effect of high-dose metreleptin on levels of omentin-1, we administered 0.1 mg kg − 1 of metreleptin to healthy individuals (n = 15) subcutaneously. Blood samples were obtained at 30 min, 1, 6, 12 and 18 h after the metreleptin administration.
Study 5: Ex vivo treatment of omental fat with leptin. To evaluate whether leptin has an acute effect on omentin-1 secretion ex vivo, we collected omental fat samples from five patients undergoing abdominal surgery, and abdominal wall subcutaneous fat in three of these patients. The samples were split in half by weight, and then cut up in small pieces. Half of each sample was incubated in control Krebs-Ringer-HEPES buffer (20 mmol l − 1 , pH 7.4) containing 2.5% bovine serum albumin and 200 nmol l − 1 adenosine, and the other sample was incubated with leptin 100 ng ml − 1 (ProSpec Bio, East Brunswick, NJ, USA). After 20 h of incubation at 37°C with gentle rocking, the supernatant was collected from all the samples for omentin-1 measurement by enzyme-linked immunosorbent assay.
Hormone assays
Serum omentin-1 was measured using an enzyme-linked immunosorbent assay (Biovendor, Candler, NC, USA). The assay had an intra-assay coefficient of variation (CV) of 3.7% and an interassay CV of 4.6%. The lower limit of detection was 2 ng ml − 1 . Leptin was measured with a radioimmunoassay (Leptin RIA; Linco Research, St Louis, MO, USA; now Millipore, Billerica, MA, USA) with an interassay CV of 6.2% and an intraassay CV of 8.3%. Serum-soluble TNF-α receptor II was measured with an enzyme-linked immunosorbent assay (R&D Systems, Minneapolis, MN, USA) with an intra-assay CV of 4.4%, inter-assay CV of 6.1% and a lower limit of detection of 7.8 pg ml − 1 . Serum interleukin-6 (IL-6) was measured with an enzyme-linked immunosorbent assay (R&D Systems) with an intraassay CV of 7.4%, inter-assay CV of 7.8% and a lower limit of detection of 0.156 pg ml − 1 . All samples were run in duplicates using standardized laboratory techniques. Stability of leptin and omentin-1 was confirmed with multiple freeze-thaw cycles.
Statistical methods
Statistical analysis was performed using Stata version 11.1 (Stata Corp., College Station, TX, USA), SAS version 9.3 (SAS Institute Inc., Cary, NC, USA) and Sigmaplot version 12.0 (Systat Software Inc., San José, CA, USA). The descriptive characteristics of the study groups are expressed as mean and standard error of the mean for continuous variables, or percentage and number for categorical variables. Variables were assessed for normality using P-P plots and the Shapiro-Wilk's test, and transformed if needed.
Analysis for day-night variation was performed using Pulse XP (University of Virginia, Charlottesville, VA, USA). To evaluate for day-night variability at the level of each subject, we used the cosine routine that fits a four-parameter cosine function to the time series of each subject's hormonal levels, against the standard deviation between duplicate measurements allowing the evaluation of the amplitude, period and phase of the oscillations on a subject-to-subject basis. To evaluate for potential day-night variability of omentin-1 levels across all study participants, we fit four-parametric nonlinear ordinal least-squares trigonometric regression models with constrained period at 24 h, evaluating potential amplitude, periodicity and phase agreement. The adjusted nonlinear coefficient of determination (R 2 ) was calculated using these models.
For study 3, we analyzed our data using hierarchical, mixed-effects linear regression models. Hormone levels were modeled as a linear function of time. Condition (fed, fasting with placebo or fasting with metreleptin) was introduced at the level-2 specification using dummy encoding. Model selection was performed using the Akaike and the Bayesian information criteria. The optimal model fit in our data was a two-level model with random intercept but fixed slope with heterogeneous first-order autoregressive residual covariance structure. For studies 2 and 4, we used repeated-measures analysis of variance with least significant difference post hoc testing.
A two-sided P-value of o0.05 was considered significant. Table 1 shows the baseline characteristics of the participants in each study. Study 1: Study in the isocaloric fed state: omentin-1 shows no circadian variation. Figure 1 shows the mean omentin-1 level over 24 h. No significant day-night variation was noted (P = 0.92, adjusted R 2 o 0.0001). . However, serum levels of omentin-1 did not change (301 ± 22, 342 ± 29, 271 ± 25 and 300 ± 29 ng ml − 1 at 0, 3, 6 and 12 months, respectively, P = 0.17). Subgroup analyses by type of surgery (Roux-en-Y vs gastric banding) or diabetes status also did not show a significant difference.
RESULTS
Study 3: Study in the fasting state with placebo/physiologic metreleptin in physiologic doses: omentin-1 levels do not change with acute fasting or with metreleptin injections. Mean omentin-1 levels were 263 ± 48 ng ml − 1 in the fed state, and did not change with fasting (231 ± 38 ng ml − 1 , P = 0.58) or fasting along with metreleptin administration in physiologic replacement doses (331 ± 63 ng ml − 1 , P = 0.25). The slopes of the omentin-1 level trajectories across time were nonsignificant, meaning that omentin-1 levels did not change during the 24 h of the study. The latter was true for all three states (P-value for slope: P = 0.27, P = 0.95 and P = 0.32 for fed, fasting and fasting with metreleptin, respectively).
Study 4: Study in the fasting state with pharmacologic doses of metreleptin: acute hyperleptinemia leads to a reduction in omentin-1 levels but no change in inflammatory cytokines. After administration of pharmacologic doses of metreleptin, serum leptin levels reached a peak mean concentration of 135 ± 33 ng ml − 1 (Figure 2a ). Omentin-1 levels dropped significantly (Figure 2b , P = 0.03). There was a trend toward an increase in soluble TNF-α receptor II, a marker of activation of the TNF-α system (Figure 2c , P = 0.12). There was also trend toward an increase in interleukin-6 levels (Figure 2d , P = 0.13), but these were not statistically significant. When performing post hoc comparisons of IL-6 levels between the values at 0, 0.5 and 1 h on one hand and to the values at 6, 12 and 18 h on the other, there was a statistically significant increase (P = 0.001). Similarly, when comparing the baseline TNF-α receptor II levels to the levels at 30 min, there was a statistically significant increase (P = 0.004). However, larger studies are needed to fully quantify effects on inflammatory makers.
Study 5: Study in the fasting state with pharmacologic doses of metreleptin: omentin-1 is not secreted from subcutaneous fat, and secretion from omental fat is not altered by leptin. Omentin-1 levels from subcutaneous adipose tissue were below the level of detection of our assay but were present in omental fat. Omentin-1 levels did not change with ex vivo exposure of omental fat to leptin (163 ± 52 vs 158 ± 48 ng ml − 1 , P = 0.85).
DISCUSSION
Obesity, especially visceral adiposity, is an inflammatory state. Adipose tissue is known to synthesize and release adipokines, and cytokines such as TNF-α and IL-6. 29 Leptin, which is secreted in higher levels from subcutaneous fat depots, 30 is known to increase macrophage and monocyte proliferation rates, thereby increasing the levels of inflammatory cytokines (TNF-α, IL-6). 31 On the other hand, omentin-1 is predominantly secreted from visceral adipose tissue 4, 5 and has an anti-inflammatory role by preventing the TNF-α-induced inflammation. 27, 32 Given the roles of both leptin and omentin-1 in obesity and chronic inflammation, we investigated whether an interaction exists between leptin and omentin-1. We also studied the physiology of omentin-1 in humans, specifically evaluating for any potential day-night variation in omentin-1 circulating levels and for omentin-1's response to starvation and leptin administration in humans.
Our study demonstrates that in contrast to leptin, there is no day-night variation in omentin-1 levels. This is in agreement with a prior study, which reached the same conclusion but was limited due to the paucity of measurements (every 30 min from 0800-1000 hours, but then only every 2 h, and only one measurement between midnight and 0800 hours). 6 We also demonstrate, for the first time in humans, that acute energy deprivation, induced by 3 days of fasting, does not alter omentin-1 levels. Interestingly, we failed to demonstrate any change in omentin-1 levels with chronic energy deprivation and weight loss following bariatric surgery. This comes in contrast with prior studies demonstrating that weight loss from a very low-calorie diet, 13 metformin 32, 33 or an aerobic exercise program 14 led to an increase in omentin-1 levels, but this might be explained by loss of more subcutaneous tissue as compared with visceral adipose tissue after bariatric surgery. 34 As omentin-1 is primarily secreted from the visceral adipose tissue, bariatric surgery and other interventions that lead to preferential loss of subcutaneous fat may have less effect on omentin-1 levels. It is unclear if our results are due to the direct effects of bariatric surgery or to other unmeasured factors.
Our study also demonstrates that high-dose metreleptin administration leads to a marked reduction in omentin-1 levels in vivo, but not ex vivo (leptin 100 ng ml − 1 ), suggesting that this is most likely mediated via intermediary factors, activated by in vivo leptin administration and not directly by leptin (which would have expected to alter omentin-1 levels ex vivo). In view of the known effects of leptin as a proinflammatory cytokine and proposed role of omentin-1 in inflammation, we also studied whether inflammatory cytokines were altered by high-dose metreleptin. We found that levels of both soluble TNF-α receptor II and IL-6 show a trend toward increase after metreleptin administration, but these changes achieve statistical significance only when time points are consolidated together. Thus, whether the changes in omentin-1 could be attributable to the changes in either TNF-α receptor II or IL-6 remains a possibility and needs be fully confirmed by future, larger studies.
A limitation of our study is that we cannot exclude changes in the samples due to prolonged storage. However, all the samples were stored under the same conditions and evaluation of the assays showed stability with multiple freeze-thaw cycles. Random error in laboratory measurements also remains a possibility but this would have been expected to only suppress effect estimates and could have not lead to the statistically significant results presented herein.
In conclusion, our physiologic study demonstrates that omentin-1 does not display any day-night variation and that omentin-1 levels remain unaltered in from both acute and chronic energy deprivation. Thus, omentin-1 levels can be measured at any time of the day irrespective of fasting or fed state. In addition, we show that pharmacologic doses of leptin decrease circulating levels of omentin-1 through an indirect mechanism that does not involve the TNF-α or IL-6 system. Whether changes in other hormones or cytokines downstream of leptin and/or leptin-induced activation of the central nervous system could be responsible for these changes in omentin-1 remains to be fully elucidated by future studies.
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